You have 9 free searches left this month | for more free features.

Mylotarg

Showing 1 - 25 of 71

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Post Marketing Surveillance (PMS) Study of Mylotarg

Not yet recruiting
  • Acute Myeloid Leukemia
    • (no location specified)
    Apr 12, 2022

    Leukemia, Myeloid, Acute Trial in Jerusalem (Vyxeos, Mylotarg)

    Recruiting
    • Leukemia, Myeloid, Acute
    • Jerusalem, Yerushalayim, Israel
      Shaare Zedek Medical Center
    Oct 25, 2022

    Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

    Active, not recruiting
    • Acute Myelogenous Leukemia
    • Myelodysplastic Syndrome
    • Gemtuzumab Ozogamicin
    • Valhalla, New York
      New York Medical College
    Sep 26, 2022

    Leukemia, Myeloid, Acute Trial in Canada, United States (VOR33, Mylotarg)

    Recruiting
    • Leukemia, Myeloid, Acute
    • VOR33
    • Mylotarg
    • La Jolla, California
    • +8 more
    Jan 31, 2023

    Patients Diagnosed With Acute Myeloid Leukemia Who Received

    Completed
    • Leukemia, Myeloid, Acute
    • Gemtuzumab Ozogamicin
    • New York, New York
      Pfizer Investigational Site
    Jul 16, 2021

    Acute Myeloid Leukemia Trial in Tampa (Vyxeos, Gemtuzumab Ozogamicin)

    Recruiting
    • Acute Myeloid Leukemia
    • Tampa, Florida
      Moffitt Cancer Center
    Sep 23, 2022

    Acute Myeloid Leukemia Trial in Memphis (Venetoclax, Azacitidine, Cytarabine)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Jul 21, 2023

    Acute Myeloid Leukemia Trial in Germany (MODULE: conventional chemo (Cytarabine+Daunorubicin) in combination with

    Active, not recruiting
    • Acute Myeloid Leukemia
    • MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO
    • +4 more
    • München, Bayern, Germany
    • +10 more
    Aug 31, 2021

    Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

    Active, not recruiting
    • Acute Myelogenous Leukemia
    • Myelodysplastic Syndrome
    • Gemtuzumab Ozogamicin
    • Valhalla, New York
      New York Medical College
    Nov 11, 2021

    Drug/Agent Toxicity by Tissue/Organ, Leukemia, MDS Trial in Chicago, Kankakee (amifostine trihydrate, cytarabine, mitoxantrone

    Withdrawn
    • Drug/Agent Toxicity by Tissue/Organ
    • +3 more
    • amifostine trihydrate
    • +2 more
    • Chicago, Illinois
    • +3 more
    Jan 31, 2023

    Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,

    Recruiting
    • Recurrent Acute Myeloid Leukemia
    • Refractory Acute Myeloid Leukemia
    • Gemtuzumab Ozogamicin
    • +4 more
    • Baltimore, Maryland
    • +1 more
    Dec 13, 2022

    Novo Acute Myeloid Leukemia Trial in Spain (Mylotarg)

    Completed
    • Novo Acute Myeloid Leukemia
    • Mylotarg
    • Badalona, Barcelona, Spain
    • +5 more
    Jan 26, 2021

    Acute Myeloid Leukemia Trial in New York (CPX-351, Gemtuzumab Ozogamicin)

    Recruiting
    • Acute Myeloid Leukemia
    • New York, New York
      Weill Cornell Medical College
    Dec 21, 2021

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

    Recruiting
    • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
    • +5 more
    • Gemtuzumab Ozogamicin
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia Trial in New York (Fludarabine, Busulfan,

    Completed
    • Acute Myelogenous Leukemia
    • +2 more
    • New York, New York
      Columbia University Medical Center
    Aug 4, 2021

    Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)

    Active, not recruiting
    • Acute Myeloid Leukemia
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 10, 2022

    Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

    Active, not recruiting
    • Recurrent Acute Myeloid Leukemia
    • Refractory Acute Myeloid Leukemia
    • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 25, 2022

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

    Recruiting
    • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
    • +3 more
    • Gemtuzumab Ozogamicin
    • Liposome-encapsulated Daunorubicin-Cytarabine
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 2, 2021

    Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow

    Recruiting
    • Acute Myeloid Leukemia
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2022

    ECG, Pharmacokinetics, Safety Trial in Worldwide (Gemtuzumab Ozogamicin)

    Completed
    • ECG
    • +2 more
    • Gemtuzumab Ozogamicin
    • Augusta, Georgia
    • +23 more
    Feb 28, 2022

    Acute Myeloid Leukemia Trial in Heidelberg (Bortezomib, Gemtuzumab Ozogamicin)

    Recruiting
    • Acute Myeloid Leukemia
    • Heidelberg, Baden-Württemberg, Germany
      University Hospital Heidelberg, Internal Medicine V
    May 25, 2020

    Acute Promyelocytic Leukemia Trial in Worldwide (Mylotarg, Arsenic Trioxide, All-trans retinoic acid)

    Recruiting
    • Acute Promyelocytic Leukemia
    • Mylotarg
    • +2 more
    • Brussels, Belgium
    • +30 more
    Aug 9, 2022

    Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute

    Recruiting
    • Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
    • +9 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 27, 2021

    Acute Myeloid Leukemia Trial in Austria, Germany (Gemtuzumab Ozogamicin (Mylotarg), standard chemo)

    Completed
    • Acute Myeloid Leukemia
    • Gemtuzumab Ozogamicin (Mylotarg)
    • standard chemotherapy
    • Graz, Austria
    • +59 more
    Sep 28, 2021

    Leukemia, Myeloid, Acute Trial in United States (VCAR33)

    Not yet recruiting
    • Leukemia, Myeloid, Acute
    • VCAR33
    • La Jolla, California
    • +9 more
    Aug 14, 2023